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Abstract
Background: C. difficile infection is transmitted via spores and the disease is mediated via
secreted toxins. It represents a significant healthcare problem and clinical presentation can
range from asymptomatic carriage to life-threatening pseudomembranous colitis.
Sources of data: publications in the field, with a focus on recent developments and concepts
Areas of agreement: infection control measures, antibiotic stewardship, current management
of the initial episode of C. difficile infection
Areas of controversy: selection and sequence of interventions for the management of
recurrent C. difficile infection; management of persistent carriers of toxigenic C. difficile in
patients at high risk of subsequent C. difficile infection
Growing points: use of faecal microbiota transplantation for recurrent C. difficile infection
Areas timely for developing research: role of specific microbiota-mediated interventions and
vaccination in the treatment and prevention of C. difficile infection
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Introduction
Description of Clostridium difficile was reported in 1935, following its isolation from healthy
infant faeces and it was originally named Bacillus difficile (1). C. difficile is a spore-forming,
Gram-positive anaerobic bacterium, which was identified in the 1970s as the aetiological agent
of antibiotic-associated pseudomembranous colitis (2). Recently, based on phenotypic,
chemotaxonomic and phylogenetic analyses, reclassification of Clostridium difficile as
Clostridioides difficile has been proposed (3).
In 2011, the estimated number of incident C. difficile infections in the United States was
453,000 and an estimated 29,300 associated deaths (4). There was a marked increase in the
number of reported cases of C. difficile infection around mid-2000 (in 2007/08, >55,000 cases
were reported by NHS Trusts in England), which included outbreaks associated with a more
virulent strain (ribotype 027) of C. difficile. The emergence of ribotype 027 is believed to have
been driven by the use of fluoroquinolone antibiotics and a recent study has proposed a role for
the increase (since 2000) in the human diet of the disaccharide trehalose, which this strain is
able to metabolise at low concentrations (5). Trehalose is a stable sugar, which may be found
in foods such as pasta, minced beef and ice cream. There is also increasing recognition of the
occurrence of C. difficile infection in the community, often in patients who have previously
had in-patient and/or out-patient exposure to the hospital setting.
Since 2007/08 there has been a progressive decline in the number of reported cases of C.
difficile infection in UK and the numbers have been fairly stable since 2013/14, (when 13,362
cases were reported). Over 12 months to 31st March 2018, 13,286 cases of C. difficile infection
were reported by NHS Trusts in England to Public Health England. As in the past, rates of
infection are highest among those over the age of 65 years, especially those over the age of 85
years (6). The decrease in incidence rates of C. difficile infection since 2007/08 appears to be
due largely to infection prevention and control measures and antimicrobial stewardship
interventions.
Although there have been large reductions in incidence rates, C. difficile infection continues to
represent a significant healthcare problem. This was illustrated in a recent population-based
study that showed an almost three-fold increase in 30-day all-cause mortality and more than
20% mean increase in additional length of stay beyond the infection. The greatest impact of C.
difficile infection was seen in the elderly. Over the 6-year period of the study (2010 – 2016),
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there appeared to be no improvement on the impact of C. difficile infection on mortality or
additional length of stay (7), implying the need to ensure timely and optimal clinical
management of patients with this infection.
Pathogenesis
The normal resident colonic bacteria are widely recognised to provide protection against
colonisation by pathogenic bacteria such as C. difficile and this defence is designated
colonisation resistance (8, 9). There is significant current interest in the characterisation of the
protective resident bacteria and the mechanisms by which they resist colonisation by C.
difficile. Recognition of normal protection by resident microbiota provides the rationale for the
use of faecal microbiota transplantation in patients with recurrent C. difficile infection (see
below), which aims to repopulate the colon with the bacteria that mediate colonisation
resistance. Such protection is disrupted by broad-spectrum antibiotics, which represent a major
risk factor for C. difficile infection.
High risk broad-spectrum antibiotics that predispose to C. difficile infection include
clindamycin, fluoroquinolones and second/third generation cephalosporins. Recent studies
using metagenomic, metatranscriptomic and metaproteomic analyses and metabolomics (study
of microbe-derived small molecules) have shown that these antibiotics lead to major depletion
and disruption of the resident colonic bacteria present in the lumen and mucosal surface, with
associated changes in the functions of the microbial communities (10, 11). The functional
impact includes alterations in bacterial metabolism of carbohydrates, amino acids and bile
acids.
The association between C. difficile infection and the use of chemotherapy for cancer treatment
(without antibiotics) has been recognised for >20 years (12). The risk may be increased in
patients with prolonged hospitalisation and those who receive both chemotherapy and
antibiotics.
In view of the reported association with this class of drugs, the diagnosis of C. difficile infection
usually leads to the review of the indication(s) for the use of proton pump inhibitors. Further
studies are required to determine the impact of stopping proton pump inhibitor treatment on
the subsequent risk of C. difficile infection.
5
Only toxigenic strains of C. difficile are responsible for the infection leading to inflammation
in the colon that is mediated by secreted toxins A and B (2, 13). Non-toxigenic strains of C.
difficile are non-pathogenic and one strain has been studied as a treatment option in patients
with recurrent disease (see below).
Secreted toxins A and B are major determinants of the disease induced by C. difficile. These
large (>200 kDa) toxins are potent inducers of the secretion of pro-inflammatory mediators and
cell death. There has also been significant interest in host cell receptors, cellular uptake and
intracellular mechanisms of actions of the toxins (13).
Studies have demonstrated the importance of the host immune response to the toxins in
determining the susceptibility to disease and risk of recurrence (2). Some of the therapeutic
approaches discussed below have targeted C. difficile toxins.
Clinical features and assessment of disease severity
Following colonisation with toxigenic C. difficile, the wide spectrum of clinical presentation
ranges from asymptomatic carriage to mild diarrhoea to life-threatening pseudomembranous
colitis (14).
A number of criteria have been used to define severe disease and have included clinical features
(bowel frequency, abdominal pain/tenderness, pyrexia) results of blood tests (peripheral white
blood cell count, serum creatinine level, albumin level), the presence of pseudomembranous
colitis (during endoscopic examination) and extent / severity of colitis upon imaging via CT
scan.
Patients with mild C. difficile infection may be considered to be those with bowel frequency
less than 4 times over 24 hours and with normal white blood count and creatinine level. In
recent guidelines (15), patients with non-severe disease are defined as those with peripheral
white blood count <15,000 cells per ml and a serum creatinine level <1.5 mg/dl (<132.6
µmol/L). Those with severe disease are deemed to have white blood count and creatinine level
above these values. Severe complicated or fulminant colitis is considered to be present in those
with hypotension or shock, ileus, megacolon and some of these patients may require admission
to intensive care unit.
Recurrence of C. difficile infection
Recurrence of C. difficile infection occurs in 10 – 35% of patients, usually within 8 weeks of
completion of treatment and may be due to the original strain or new strain of C. difficile (14,
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15). Risk factors for recurrence include previous episodes of C. difficile infection, host immune
response to C. difficile toxins, additional antibiotics, old age, severe underlying disease(s) and
the use of proton pump inhibitors. Treatment options for recurrent C. difficile infection are
discussed below.
Inflammatory bowel disease (IBD) and C. difficile infection
A number of studies have reported an increase in the risk of C. difficile infection in patients
with inflammatory bowel disease (2, 15). The risk may be greater in patients with ulcerative
colitis but a recent study, which reported a 4.8-fold increase in C. difficile infection in patients
with IBD, found no difference between those with ulcerative colitis and Crohn’s disease (16).
It should be noted that pseudomembranes (or characteristic histological changes) may not be
seen in IBD patients with C. difficile infection (2). Worse clinical outcomes have been reported
in IBD patients with C. difficile infection, including longer duration of residence in hospital,
increased colectomy rates and higher mortality rates (17). The potential mechanisms by which
C. difficile infection may enhance mucosal inflammatory responses in IBD have been reviewed
(2).
Diagnosis and investigations
The diagnosis of C. difficile infection is usually considered in those presenting with diarrhoea
following exposure to antibiotics and requires collection of stool samples. Before the
establishment of the relevant enzyme immunoassays (EIAs) and molecular tests for toxin
genes, the diagnosis of C. difficile infection was based predominantly on culture of toxigenic
C. difficile (followed by confirmation of its capacity to produce toxins) or a positive cell culture
cytotoxicity neutralization assay. These tests are time consuming and now represent reference
methods. Additionally, C. difficile culture and molecular typing is used for the detection of
outbreaks and epidemiologic studies. Because of their convenience, enzyme immunoassays for
toxin A or both toxins (A and B) were introduced in clinical laboratories in the late 1980s (15).
The performance of these commercial EIAs was variable, with reasonable specificity but low
sensitivity. Newer EIAs have tended to perform better but in order to improve sensitivity, other
tests were introduced. They include immunoassays for glutamate dehydrogenase (GDH, which
is expressed by all isolates of toxigenic and non-toxigenic C. difficile) and molecular [nucleic
acid amplification test (NAAT) and polymerase chain reaction (PCR)] tests for the detection
of toxin gene. These assays are highly sensitive (>90%) for the presence of C. difficile in a
stool sample and therefore have a high negative predictive value (>95%) for C. difficile
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infection. However, GDH immunoassays and molecular tests for toxin gene have a low (<50%)
positive predictive value for the infection.
From 2012, a two-test protocol has been established in UK hospitals for the diagnosis of C.
difficile infection. An initial screening test is undertaken to look for the presence of C. difficile
via GDH immunoassay or molecular test for toxin gene. If positive, a second test is undertaken
to look for the presence of C. difficile toxins using a sensitive enzyme immunoassay (18).
If the molecular test for C. difficile toxin gene is positive but the stool sample is negative for
toxin EIA, the patient is deemed to be a carrier (excretor) of toxigenic C. difficile and has
potential for transmission to others (see below).
Since the stool samples are usually only tested from patients with diarrhoea and since
sensitivities of the toxin EIAs are usually <90%, some patients with C. difficile infection may
be misdiagnosed as carriers (and the diarrhoea attributed to another cause). The demonstration
of characteristic pseudomembranous colitis at flexible sigmoidoscopy (which can be
undertaken without bowel preparation) may enable the diagnosis of C. difficile infection when
the stool tests are equivocal or negative despite strong clinical suspicion. Together with
biopsies (which on histological examination may show “summit lesions” characteristic of
pseudomembranous colitis), such endoscopic examinations may also be helpful in the rapid
diagnosis and assessment of those with severe symptoms, and may also identify other causes
of diarrhoea such as such as inflammatory bowel disease, ischaemic colitis and
microscopic/collagenous colitis (19). Additionally, stool samples can be collected during the
endoscopic procedure.
Assessment of disease severity
Predictors of 30-day mortality include a high leukocyte count and elevated creatinine and
lactate levels (14, 20). In those with significant clinical features, CT abdomen enables
assessment of the extent and severity of colonic inflammation. Abdominal x-ray is often helpful
for the detection of complications such as toxic megacolon or perforation. For those with
features of colitis on CT imaging but equivocal stool test result, flexible sigmoidoscopy &
biopsy may be required to confirm the diagnosis of C. difficile-associated pseudomembranous
colitis.
Infection control
Patients with suspected infectious diarrhoea should be accommodated in a single room with a
self-contained toilet and its own hand basin. If such facilities are not available, patients with
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confirmed C. difficile infection may be nursed in a dedicated ward or multibed room, with strict
infection control measures.
In addition to isolation, contact precautions should be undertaken and include wearing gowns
and gloves when caring for patients with C. difficile infection. Hand washing with soap and
water is recommended to remove C. difficile spores. Following discharge, the room that had
been occupied by a patient with C. difficile infection should be disinfection.
With increasing appreciation of antibiotic resistance in clinical practice, antibiotic stewardship
programs are widely adopted with the aim to use narrow-spectrum antibiotics for documented
infection, for the shortest duration. For the control of C. difficile infection, this usually involves
restriction in the use of fluoroquinolones, third-generation cephalopsorins, clindamycin and
amoxicillin. Such measures are deemed particularly important for those at greatest risk,
including those with previous episodes of C. difficile infection and carriers of toxigenic C.
difficile.
Carriage of toxigenic C. difficile
In a systematic review and meta-analysis, asymptomatic patients colonised with toxigenic C.
difficile had a 5.9 times higher risk of subsequent C. difficile infection compared to those who
were not colonised (21). There is also an increased risk of C. difficile infection in hospitalised
patients exposed in the ward to asymptomatic carriers of toxigenic C difficile (22). Moreover,
detection and isolation of asymptomatic carriers of toxigenic C. difficile has been reported to
lead to a decrease in the incidence of health care-associated C. difficile infection (23). The risk
of transmission is likely to be greater in carriers of toxigenic C. difficile with diarrhoea due to
another cause. With the use of the two-test protocol for the diagnosis of C. difficile infection,
there is increasing recognition of this group of patients, in which infection control measures
should be undertaken.
Since asymptomatic carriers of toxigenic C. difficile are at an increased risk of developing (and
transmitting) C. difficile infection, selected patients could be considered for intervention. Such
an approach is being investigated for high risk patients such as those undergoing bone marrow
transplantation (24, 25).
Treatment of C. difficile infection.
Oral vancomycin and metronidazole have been used for the treatment of C. difficile infection
since the 1970s. Although initial small studies reported no significant difference in responses
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to these two antibiotics, more recent studies have demonstrated the superiority of vancomycin
for not only severe C. difficile infection, but also mild-to-moderate disease (reviewed in (15,
20). Together with reduction in its cost (especially the use of intravenous formulation for oral
administration), vancomycin has increasingly been the antibiotic of choice for C. difficile
infection of any severity.
In 2011 fidaxomicin was approved by the European Medicines Agency and the Food and Drug
Administration for the treatment of C. difficile infection. It is a macrocyclic antibiotic with a
narrow spectrum of antibacterial activity against C. difficile, with moderate activity against
some other Gram-positive bacteria. It is very poorly absorbed systemically and achieves high
faecal concentrations after oral administration. In two randomised controlled trials,
fidaxomicin (dose 200 mg twice daily for 10 days) was non-inferior to vancomycin (125 mg
four times daily for 10 days) in rates of clinical cure (defined as resolution of diarrhoea and no
further need for treatment) in patients with mild to severe C. difficile infection. Recurrence
rates were significantly lower in those who received fidaxomicin, except in the subgroup of
patients infected with the ribotype 027 strain of C. difficile (26, 27). Adverse events did not
differ significantly between vancomycin and fidaxomicin. Thus, vancomycin or fidaxomicin
have recently been recommended for the treatment of C. difficile infection that is mild to severe
(15). In view of its cost, vancomycin is often used for an initial episode of C. difficile infection
and fidaxomicin reserved for those with recurrence. Because of higher cure rates (compared to
vancomycin) in patients receiving concomitant antibiotics for other infections, fidaxomicin is
currently the antibiotic of choice in this group of patients.
Patients with severe complicated or fulminant C. difficile infection were not included in the
above studies and is currently usually treated with high dose (500 mg q.d.s) oral vancomycin
and intravenous metronidazole. In the presence of ileus, adequate amounts of oral vancomycin
may not reach the colon but intravenous metronidazole is secreted in the lumen of the inflamed
colon. Rectal vancomycin may also be used in such patients.
Surgery may be required for some with severe complicated or fulminant disease. This usually
involves a subtotal colectomy but a recent report suggests a role for loop ileostomy (which
could be undertaken laparoscopically in the majority of the patients) and instillation of
vancomycin into the preserved colon via the ileostomy (28).
Treatment for recurrent C. difficile infection
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A number of approaches have been used for the treatment of first recurrence: course of
vancomycin (if metronidazole was used to treat the initial episode), fidaxomicin (if vancomycin
was used to treat the first episode). Subsequent recurrence is often treated with vancomycin in
a tapered and pulsed regimen.
Recently, there has been increasing use of faecal microbiota transplantation for those patients
who have had 2 or more recurrences of C. difficile infection (see below).
Recently-investigated non-antibiotic-based treatment strategies
Since the C. difficile infection is often preceded by the use of broad-spectrum antibiotics, there
is interest in the development of non-antibiotics-based approaches to treatment and prevention
of this infection. Such approaches are based on the knowledge of disease pathogenesis such as
the permissive environment created by broad spectrum antibiotics that allows colonisation by
toxigenic C. difficile due to the loss of protective resident bacteria. Following colonisation,
there is an essential requirement for secreted toxins to mediate the intestinal inflammation.
For treatment of established infection, the secreted C. difficile toxins have been targeted with
aim of inhibiting their interactions with the host mucosal cells. Tolevamer is an anionic
polymer that noncovalently binds C. difficile toxins A and B and following a promising phase
2 study, was investigated for the treatment of mild to moderately severe C. difficile infection
in two randomised controlled trials (29). Less than 50% of patients responded to tolevamer as
monotherapy, which was significantly less effective than either metronidazole or vancomycin.
Compared to metronidazole and vancomycin, recurrence of disease was significantly lower in
those who responded tolevamer, which could be due persistence of protective components of
the microbiota. It is of interest that those who responded to tolevamer retained high counts of
C. difficile, which gradually declined and by day 42 levels were similar to those in the antibiotic
treated groups (30).
Bezlotoxumab is a human monoclonal antibody that is capable of neutralizing toxin B by
blocking its binding to host cells. In a report of two phase 3 trials, bezlotoxumab as single
infusion during standard antibiotic treatment for C. difficile infection was associated with
significantly lower rate of recurrent infection, when compared with placebo (in pooled analysis,
27% of those who received placebo had recurrence of C. difficile infection at 12 weeks,
compared to 17% of those who had bezlotoxumab) (31). Bezlotoxumab has been approved for
use in many countries for the prevention of recurrence of C. difficile infection. It is anticipated
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that further studies will enable assessment of the role of this treatment, which is given in
addition to standard antibiotics.
Non-toxigenic strains of C. difficile do not secrete toxins as they lack the relevant genes and
therefore do not cause disease. In studies undertaken in 1980s, hamsters colonised by non-
toxigenic strains of C. difficile were shown to be protected from infection by a toxigenic strain
(32). In a more recent phase 2 study involving patients that had recently completed a course of
antibiotics for C. difficile infection, oral administration of spores of a non-toxigenic strain of
C. difficile significantly reduced the recurrence of C. difficile infection (33). It is postulated
that colonisation by non-toxigenic C. difficile would provide protection by competing against
toxigenic strains of C. difficile for the relevant niche in the colon.
Faecal microbiota transplantation (FMT)
FMT has been of interest for many years, with many anecdotal reports of success in the
treatment of recurrent C. difficile infection. Over the last few years, there has been resurgence
of interest following the report in 2013 of the first randomized trial in which duodenal infusion
(via nasoduodenal tube) of donor faeces was significantly more effective than vancomycin for
the treatment of recurrent C. difficile (34). Subsequent randomized trials have demonstrated
efficacy of FMT, administered via different routes (oral capsules, nasogastric tube,
colonoscopy, enema), in the treatment of recurrent C. difficile infection (15, 35). Whilst studies
suggest that instillation at colonoscopy may be lead to highest rates of success, procedure-
related risks of adverse events are likely to be lower following administration via oral capsules
or enema and these routes also offers the scope for more convenient repeat administration.
Studies to date have reported short-term efficacy and safety of FMT with predominantly mild
to moderate self-limited adverse events that are largely related to the gastrointestinal tract (15,
35). However, there is a need for the demonstration of long-term safety of this treatment.
Currently, FMT treatment is usually considered in a patient with two or more recurrences of
C. difficile infection (20).
The mechanism(s) by which FMT mediates therapeutic benefit in patients with recurrent C.
difficile infection is unknown but is of significant current interest. It is postulated to be via the
restoration of the characteristics of the resident microbiota that mediate colonisation resistance
to C. difficile. Patients with recurrent C. difficile infection have been shown to express a
decrease in diversity of the gut microbiota (36). Structural and functional features of the
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resident microbiota that may be re-establish by FMT include the metabolism of carbohydrates,
amino acids, lipids (including fermentation into short chain fatty acids) and bile acids (10, 36).
A number of studies suggest that colonization resistance to C. difficile may be restored via
bacteria-mediated re-establishment of bile acid metabolism that leads to the generation of
secondary bile acids following 7 alpha-hydroxylation of primary bile acids that reach the colon
(2). Competition for metabolites and nutrients may represent other mechanisms by which FMT
restores colonization resistance against C. difficile.
Antibiotic-induced loss of colonization resistance has been reported to be re-established in
mice using a mixture of 6 bacterial species (37), implying future prospect for the development
of similar defined bacteriotherapy for patients with recurrent C. difficile infection. However,
challenges for the development of such therapy are illustrated by the recent demonstration that
some probiotic bacterial species may delay the re-establishment of the microbiome to the state
that existed prior to disruption by antibiotics (11).
In an open-label pilot study, donor stool suspensions that were sterilized by filtration have been
reported to lead to the resolution of recurrent C. difficile infection in 5 patients (38). This study
suggests that the beneficial effects of FMT may not require bacteria to mediated therapeutic
benefits which could be derived from the bacterial products, components and/or
bacteriophages. It is anticipated that future controlled studies will determine the role of sterile
faecal filtrates in the management of patients with recurrent C. difficile infection.
Vaccination
Active immunization aims to generate a protective systemic and / or mucosal immune
responses in those at greatest risk of developing C. difficile infection. Although no vaccine is
currently approved for clinical use, there are ongoing clinical trials that have been undertaken
following studies in animals (39).
Majority of the studies have targeted toxins A and B because they represent the main virulence
determinants of C. difficile infection, and anti-toxin antibodies have been associated with
protection against C. difficile infection and its recurrence (2). Inactivated whole toxins and their
recombinant fragments have been used as vaccines. More recently, DNA vaccines have also
been studied. Since vaccines against the toxins may not provide protection against colonisation,
bacterial surface antigens involved in adhesion to intestinal epithelial cells represent additional
targets.
13
Clinical trials
Following phase II trials for protection against recurrence and for prophylactic use, a phase III
clinical trial was initiated to assess the efficacy of a highly purified formalin inactivated full
length toxins A and B toxoid vaccine in preventing symptomatic primary C. difficile infection
in adults aged 50 yrs or older (39, 40). This trial was initiated in 2013, but after recruitment of
>9,000 participants, the trial was terminated because the Independent Data Monitoring
Committee concluded that the probability that the study will meet its primary objective is low
(40). A genetically modified toxins A and B toxoid vaccine is currently recruiting to a phase
III trial, aiming for >17,000 participants (41). The trial is evaluating the ability of the vaccine
to provide protection against C. difficile infection in at risk adults aged 50 years or older.
Immunogenicity and safety of this vaccine was reported in phase I and II studies (39). A
recombinant fusion protein consisting of truncated C. difficile toxins A and B completed a
phase II study in 2015 in healthy adults (42) and a phase III trial is expected to start in the near
future.
Conclusion
C. difficile infection continues to represent a significant healthcare problem in which the
majority of those affected are in the older age group and have recently been on antibiotics.
Vancomycin is increasingly used for an initial episode of C. difficile infection of any severity.
However, persistent disruption of the protective resident colonic bacteria is believed to be
responsible for recurrence of C. difficile infection that occurs in a significant proportion of
patients. There is therefore significant interest in non-antibiotics based treatments and of those
recently investigated, faecal microbiota transplantation (FMT) is increasingly used in clinical
practice for the management for those who have had multiple recurrences of C. difficile
infection. It is anticipated that greater understanding of mechanisms by which FMT mediates
therapeutic benefit will lead to the identification of new forms of treatment. Infection
prevention and control measures and antimicrobial stewardship interventions remain important
aspects of management, which are especially relevant for those with previous episodes of C.
difficile infection and asymptomatic carriers (excretors) of toxigenic C. difficile. Protection via
active immunization is currently under investigation in at risk adults aged 50 years or older.
14
References
1. HALL IC, O'TOOLE E. INTESTINAL FLORA IN NEW-BORN INFANTS: WITH A
DESCRIPTION OF A NEW PATHOGENIC ANAEROBE, BACILLUS DIFFICILIS. American
Journal of Diseases of Children. 1935;49(2):390-402.
2. Monaghan TM, Cockayne A, Mahida YR. Pathogenesis of Clostridium difficile
Infection and Its Potential Role in Inflammatory Bowel Disease. Inflammatory bowel
diseases. 2015;21(8):1957-66.
3. Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium
difficile as Clostridioides difficile (Hall and O'Toole 1935) Prevot 1938. Anaerobe.
2016;40:95-9.
4. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of
Clostridium difficile Infection in the United States. New England Journal of Medicine.
2015;372(9):825-34.
5. Collins J, Robinson C, Danhof H, Knetsch CW, van Leeuwen HC, Lawley TD, et al.
Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature.
2018;553(7688):291-4.
6. Annual epidemiological commentary: Gram-negative bacteraemia, MRSA
bacteraemia, MSSA bacteraemia and C. difficile infections, up to and including financial
year April 2017 to March 2018. Public Health England Publications. July 2018.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme
nt_data/file/724030/Annual_epidemiological_commentary_2018.pdf 2018.
7. Banks A, Moore EK, Bishop J, Coia JE, Brown D, Mather H, et al. Trends in mortality
following Clostridium difficile infection in Scotland, 2010-2016: a retrospective cohort and
case-control study. The Journal of hospital infection. 2018;100(2):133-41.
8. Borriello SP, Barclay FE. An in-vitro model of colonisation resistance to Clostridium
difficile infection. Journal of medical microbiology. 1986;21(4):299-309.
9. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal
pathogens. Nature reviews Immunology. 2013;13(11):790-801.
10. Theriot CM, Young VB. Interactions Between the Gastrointestinal Microbiome and
Clostridium difficile. Annual review of microbiology. 2015;69:445-61.
11. Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, et
al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and
Improved by Autologous FMT. Cell. 2018;174(6):1406-23.e16.
12. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic
chemotherapy: a review. Clinical infectious diseases : an official publication of the
Infectious Diseases Society of America. 1993;17(1):109-13.
13. Chandrasekaran R, Lacy DB. The role of toxins in Clostridium difficile infection.
FEMS microbiology reviews. 2017;41(6):723-50.
14. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-
associated disease. Gut. 2008;57(6):850-60.
15. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al.
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017
Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare
Epidemiology of America (SHEA). Clinical infectious diseases : an official publication of the
Infectious Diseases Society of America. 2018;66(7):e1-e48.
16. Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher Incidence
of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease.
Gastroenterology. 2017;153(2):430-8.e2.
17. Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory
bowel disease patient. Inflammatory bowel diseases. 2013;19(1):194-204.
18. Updated guidance on the diagnosis and reporting of Clostridium difficile.
Department of Health. https://www.gov.uk/government/publications/updated-guidance-
on-the-diagnosis-and-reporting-of-clostridium-difficile. . 2012.
15
19. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile
associated diarrhoea in hospitalised patients: onset in the community and hospital and
role of flexible sigmoidoscopy. Gut. 2004;53(5):673-7.
20. Guh AY, Kutty PK. Clostridioides difficile Infection. Annals of internal medicine.
2018;169(7):Itc49-itc64.
21. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization
with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic
review and meta-analysis. The American journal of gastroenterology. 2015;110(3):381-
90; quiz 91.
22. Blixt T, Gradel KO, Homann C, Seidelin JB, Schonning K, Lester A, et al.
Asymptomatic Carriers Contribute to Nosocomial Clostridium difficile Infection: A Cohort
Study of 4508 Patients. Gastroenterology. 2017;152(5):1031-41.e2.
23. Longtin Y, Paquet-Bolduc B, Gilca R, Garenc C, Fortin E, Longtin J, et al. Effect of
Detecting and Isolating Clostridium difficile Carriers at Hospital Admission on the Incidence
of C difficile Infections: A Quasi-Experimental Controlled Study. JAMA internal medicine.
2016;176(6):796-804.
24. Shah NN, McClellan W, Flowers CR, Lonial S, Khoury H, Waller EK, et al. Evaluating
Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A
National Study. Infection control and hospital epidemiology. 2017;38(6):651-7.
25. Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, et al. Oral
vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in
allogeneic hematopoietic cell transplant recipients. Clinical infectious diseases : an official
publication of the Infectious Diseases Society of America. 2018.
26. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin
versus vancomycin for Clostridium difficile infection. The New England journal of medicine.
2011;364(5):422-31.
27. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al.
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada,
and the USA: a double-blind, non-inferiority, randomised controlled trial. The Lancet
Infectious diseases. 2012;12(4):281-9.
28. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop
ileostomy and colonic lavage: an alternative to total abdominal colectomy for the
treatment of severe, complicated Clostridium difficile associated disease. Annals of
surgery. 2011;254(3):423-7; discussion 7-9.
29. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, et al.
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from
two multinational, randomized, controlled trials. Clinical infectious diseases : an official
publication of the Infectious Diseases Society of America. 2014;59(3):345-54.
30. Louie TJ, Byrne B, Emery J, Ward L, Krulicki W, Nguyen D, et al. Differences of the
Fecal Microflora With Clostridium difficile Therapies. Clinical infectious diseases : an official
publication of the Infectious Diseases Society of America. 2015;60 Suppl 2:S91-7.
31. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab
for Prevention of Recurrent Clostridium difficile Infection. The New England journal of
medicine. 2017;376(4):305-17.
32. Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile
ileocaecitis by prior colonisation with non-pathogenic strains. Journal of medical
microbiology. 1985;19(3):339-50.
33. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, et al. Administration
of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C.
difficile infection: a randomized clinical trial. Jama. 2015;313(17):1719-27.
34. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al.
Duodenal infusion of donor feces for recurrent Clostridium difficile. The New England
journal of medicine. 2013;368(5):407-15.
35. Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, et al. The
use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium
difficile infection and other potential indications: joint British Society of Gastroenterology
(BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;67(11):1920-41.
16
36. Baktash A, Terveer EM, Zwittink RD, Hornung BVH, Corver J, Kuijper EJ, et al.
Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of
Clostridium difficile Infections. Frontiers in microbiology. 2018;9:1242.
37. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, et al. Targeted
restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves
relapsing Clostridium difficile disease in mice. PLoS pathogens. 2012;8(10):e1002995.
38. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al.
Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile
Infection. Gastroenterology. 2017;152(4):799-811.e7.
39. Bruxelle JF, Pechine S, Collignon A. Immunization Strategies Against Clostridium
difficile. Advances in experimental medicine and biology. 2018;1050:197-225.
40. Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C.
Difficile Infection. . https://clinicaltrialsgov/ct2/show/study/NCT01887912.
41. Clostridium Difficile Vaccine Efficacy Trial (Clover). .
https://clinicaltrialsgov/ct2/show/study/NCT03090191.
42. Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile
Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study.
https://clinicaltrialsgov/ct2/show/study/NCT02316470.
